Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis
2019 · Journal of Crohn s and Colitis · 290 citations
https://doi.org/10.1093/ecco-jcc/jjy215
F
Flavio Caprioli
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
387
Papers
10.0K
Citations
51
h-index
135
i10-index
Flavio Caprioli is an academic researcher from University of Milan. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Immune Cell Function and Interaction. The author has an h-index of 51, co-authored 329 publications.
ORCID: 0000-0002-8077-8175Papers by this author
worksRisankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
2024 · New England Journal of Medicine · 132 citations
https://doi.org/10.1056/nejmoa2314585
Intestinal IFN-γ–producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease
2018 · Journal of Allergy and Clinical Immunology · 99 citations
https://doi.org/10.1016/j.jaci.2017.12.984
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Gastroenterology · 88 citations
https://doi.org/10.1053/j.gastro.2023.08.038
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
2024 · The Lancet · 76 citations
https://doi.org/10.1016/s0140-6736(24)01762-8
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · The Lancet · 67 citations
https://doi.org/10.1016/s0140-6736(24)01927-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat